Stoke Therapeutics Inc (STOK)

$11.69 0.00 (0.00%)

16:00 EDT STOK Stock Quote Delayed 30 Minutes

Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?

By William White, InvestorPlace Writer Mar 26, 2024

Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

More Articles

Volume:

Previous Close -

Market Cap 516.56M

PE Ratio -22.06

EPS -0.53

Volume (Avg. Vol.) 2

Day's Range -

52-Week Range $3.35 - $16.40

Dividend & Yield N/A (N/A)

STOK Stock Predictions, Articles, and Stoke Therapeutics Inc News

From InvestorPlace
From the Web

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

By Josh Enomoto, InvestorPlace Contributor Feb 19, 2024

You want speculative stocks with upside potential up to 3X returns? I’m going to give them to you. But you have to accept the risk.…

7 Stocks Due for a Stunning Short Squeeze

By Josh Enomoto, InvestorPlace Contributor Aug 9, 2022

If you have the inclination and the iron stomach for wild volatility, these intriguing short-squeeze stocks might be up your alley.

Stoke Stock (NASDAQ:STOK) Soars 73% on Drug Update; Is There More Upside Left?

From TipRanks Apr 1, 2024

Stoke Therapeutics (NASDAQ:STOK) stock soared by 73% following the report of updated data from a Phase 1/2 study of its STK-001, a drug for treating Dravet syndrome...

JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)

From Seeking Alpha Nov 25, 2023

JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.

This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

From The Motley Fool Aug 16, 2023

This small-cap biotech might be a hidden gem.

Stoke Therapeutics GAAP EPS of -$0.69 misses by $0.06 (NASDAQ:STOK)

From Seeking Alpha Aug 7, 2023

Stoke Therapeutics press release (STOK): Q2 GAAP EPS of -$0.69 misses by $0.06.As of June 30, 2023, Stoke had approximately $231.4 million in cash, cash equivalents, and...

Why Shares of Stoke Therapeutics Plummeted Tuesday

From The Motley Fool Jul 25, 2023

The company's shares fell after it released early trial results on its lead therapy.

SVB Securities Remains a Buy on Stoke Therapeutics (STOK)

From TipRanks Dec 9, 2022

SVB Securities analyst Rudy Li maintained a Buy rating on Stoke Therapeutics (STOK – Research Report) yesterday. The company’s shares closed yester...

ADVERTISEMENT